Vibegron
- Generic Name
- Vibegron
- Brand Names
- Gemtesa, Obgemsa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28N4O3
- CAS Number
- 1190389-15-1
- Unique Ingredient Identifier
- M5TSE03W5U
- Background
Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary...
- Indication
Vibegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1395
- Registration Number
- NCT01314872
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath